Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Notice of Funding Opportunity (NOFO) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.

Volunteer for COVID-19 Clinical Trials

We made history with safe and effective vaccines and we’ll keep working as long as there are people to protect, variants emerging, and research answers needed to keep us all safe. That means we still need you!

NIAID is conducting and supporting clinical trials evaluating therapies and vaccine candidates against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), as well as studies of people who have recovered from infection.

Featured COVID-19 Studies

Cartoon of a man getting an infusion
Credit
HHS

Outpatient Treatment With Anti-Coronavirus Immunoglobulin (OTAC)

A research study testing an experimental COVID-19 treatment called anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG).

Tratamiento ambulatorio con inmunoglobulina anticoronavirus

Ongoing NIAID-supported COVID-19 Studies

Browse a selection of NIAID-supported studies. A frequently updated, comprehensive list of all COVID-19 clinical trials can be found on ClinicalTrials.gov.

Find COVID-19 Clinical Trials

 

Centers for Research in Emerging Infectious Diseases (CREID)

The global network involves multidisciplinary investigations into how and where viruses and other pathogens can emerge from wildlife and spillover to cause disease in people. Research is led by 10 Centers and one Coordinating Center and will involve collaborations with peer institutions in the United States and 28 other countries.

Read more about this network: CREID Network

Main Areas of Focus

Research projects will include surveillance studies to identify previously unknown viral causes of febrile illnesses in humans, the animal sources of viral or other disease-causing pathogens, and to determine what genetic or other changes make these pathogens capable of infecting humans. Other research by the CREID investigators will involve developing reagents and diagnostic assays to improve detection of emerging pathogens as well as studies aimed at detailing human immune responses to new or emerging infectious agents. Overall, the breadth of research projects to be carried out in the CREID network will allow for study of disease spillover in multiple phases of the process: where pathogens first emerge from an animal host; at the borders between wild and more populated areas, where and when rapid human-to-human transmission occurs; and, finally, how transmission is facilitated in urban areas, where epidemic spread can occur.

Locations

Primary awardees for the CREID network and regions of focus include: 

  • Donald Brambilla, Ph.D., RTI International, Research Triangle Park, North Carolina
  • Tony Moody, M.D., Duke University School of Medicine, Durham, North Carolina
    CREID Coordinating Center
  • Kristian Andersen, Ph.D., Scripps Research, La Jolla, California
    West African Emerging Infectious Disease Research Center
    West Africa
  • Eva Harris, Ph.D., University of California, Berkeley
    American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES)
    Central and South America, South Asia
  • Christine Johnson, VMD, Ph.D., University of California, Davis, School of Veterinary Medicine
    Epicenter for Emerging Infectious Disease Intelligence
    Central Africa and South America
  • M. Kariuki Njenga, Ph.D., Washington State University, Pullman
    Center for Research in Emerging Infectious Diseases-East and Central Africa
    East and Central Africa
  • Anavaj Sakuntabhai, Ph.D., Institut Pasteur, Paris, France 
    West Africa and Southeast Asia
  • Nikos Vasilakis, Ph.D., University of Texas Medical Branch, Galveston
    Central and South America
  • Wesley C. Van Voorhis, M.D., Ph.D., University of Washington, Seattle
    South America, West and South Africa, Middle East, and Asia
  • David Wang, Ph.D., Washington University School of Medicine, St. Louis, Missouri 
    Asia, East Africa
  • Scott C. Weaver, Ph.D., University of Texas Medical Branch, Galveston
    West Africa

Contact Information

News and Announcements

Nov. 17, 2021: NIAID Supports Early-Career Researchers in Emerging Infectious Diseases

Aug. 27, 2020: NIAID Establishes Centers for Research in Emerging Infectious Diseases

Content Coordinator
Stephanie Coomes
Cynthia Rojas
Content Manager
Mason Booth

Virology—Integrated Research Facility at Fort Detrick

The virology team focuses on gaining a deeper understanding of viral pathogenesis and advancing clinical approaches to assist in managing diseases. The team works with a range of high-consequence viral pathogens.

The team leverages fundamental methodologies, such as: 

Pathology and Histology—Integrated Research Facility at Fort Detrick

The pathology and histology teams work together to conduct morphologic assessments and molecular assays using in-life and postmortem samples attained during research studies that develop and use established animal models of high-consequence emerging human viruses. The clinical pathologic and histopathologic data are interpreted by the pathologists using historical controls, or within-study controls, to generate reports that address specific pathology-associated aims of each study.

Clinical Studies Support—Integrated Research Facility at Fort Detrick

The Clinical Studies Support Team (CSST) develops and fosters overseas relationships through continuous support of research studies and clinical trials involving pathogens of high consequence. When deployed, the team provides in-person training and assistance with assays, equipment, and project management.

Immunology—Integrated Research Facility at Fort Detrick

The immunology team interrogates immune responses against pathogens requiring maximum containment by use of a variety of capabilities. These include but are not limited to cytometry (e.g., immunophenotyping), Luminex multiplex protein/cytokine arrays, cartridge-based cell- sorting (MACSQuant Tyto), ELISAs, serology, in vitro functional assays, intracellular cytokine staining (ICS) enzyme-linked immune absorbent spot (ELISPOT; e.g., T cell and B cell).

Imaging Sciences—Integrated Research Facility at Fort Detrick

The IRF-Frederick is equipped with a one-of-a-kind multi-modality imaging suite, containing both clinical and pre-clinical imaging scanners, including magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and computed tomography (CT).

Electron Microscopy (EM)—Integrated Research Facility at Fort Detrick

The electron microscopy (EM) laboratory team uses transmission electron microscopy (TEM), scanning electron microscopy (SEM), negative staining techniques and assays, immunogold labeling, quantitation of biological samples, and other specialized methods. The EM team at the Integrated Research Facility at Fort Detrick (IRF Frederick) uses these varied capabilities for the analysis of biological samples at an ultrastructural level.

Drug Screening—Integrated Research Facility at Fort Detrick

The drug screening team tests and characterizes novel compounds, drugs, and antibodies against numerous viruses in multiple cell lines under a variety of conditions. Compounds are evaluated in cell-based assays for inhibition of viral replication and reduction of virus yields, plaques, or cytopathic effect. In addition, recombinant reporter gene viruses are available as tools for antiviral screening.

Subscribe to